2 weeks Ago By ABMN Staff
Xenon Pharmaceuticals ( NASDAQ:XENE – Get Free Report ) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday. Several other analysts also recently weighed in on the stock.
Royal Bank of Canada reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Deutsche Bank Aktiengesellschaft began coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.
00 price objective on the stock. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Finally, HC Wainwright restated a “buy” rating and issued a $53.
00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.
com, Xenon Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $56.78. Read Our Latest Stock Report on Xenon Pharmaceuticals Xenon Pharmaceuticals Stock Up 4.
0 % Xenon Pharmaceuticals ( NASDAQ:XENE – Get Free Report ) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.
89) by $0.05. Analysts expect that Xenon Pharmaceuticals will post -3.
1 earnings per share for the current fiscal year. Insider Activity In other news, CEO Ian Mortimer sold 22,468 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $40.
20, for a total value of $903,213.60. Following the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,258,340.
40. This represents a 41.79 % decrease in their ownership of the stock.
The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . Company insiders own 5.52% of the company’s stock.
Institutional Investors Weigh In On Xenon Pharmaceuticals A number of large investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD.
purchased a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at $63,000. Quarry LP purchased a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $78,000. Blue Trust Inc.
boosted its stake in shares of Xenon Pharmaceuticals by 140.3% during the 4th quarter. Blue Trust Inc.
now owns 2,422 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 1,414 shares during the last quarter. Avior Wealth Management LLC purchased a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth about $101,000. Finally, KBC Group NV raised its position in shares of Xenon Pharmaceuticals by 39.
8% in the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 780 shares during the last quarter. Institutional investors and hedge funds own 95.
45% of the company’s stock. Xenon Pharmaceuticals Company Profile ( Get Free Report ) Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
